MK 0867Alternative Names: MK-0867
Latest Information Update: 30 Jan 2008
At a glance
- Originator Merck & Co
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Endocrine disorders
Most Recent Events
- 01 Aug 2006 Phase-I clinical trials in Endocrine disorders in USA (unspecified route)
- 31 Aug 2005 Phase-I clinical trials in Endocrine disorders in USA (unspecified route)